Continuous Glucose Monitoring (CGM) system is a developing technology in the field of diabetes treatment as it enables patients to effectively control and adjust their insulin therapy. Clinical trials have shown its efficacy in lowering HbAlc significantly especially in adults with type 1 diabetes and those with HbAlc >8%. Moreover, new modalities of Treating T2DM of blood glucose in type II diabetes mellitus is important to improve outcomes. In this interaction, Dr. Roger Talks about “ Glucose Monitoring in Diabetes Mellitus.
” Dr. Roger Maze is an executive director of the Diabetes Research and Training Center and the first WHO Collaborating Center. He is credited for the development of the ambulatory glucose profile (AGP) as the first standardized report from (Self-Monitoring of Blood Glucose) SMBG and CGM. He also developed and directed the first WHO-recognized technology laboratory…
